Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.
Members of Living Beyond Breast Cancer's Medical Advisory Board react to the FDA decision to withdraw approval of Avastin as a treatment for metastatic breast cancer.
Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.
FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.
NEW YORK (Reuters Health) - A diagnosis of breast cancer will inevitably sink a woman's mood, but those whose spirits lift over time appear to survive longer, a new study suggests.
NEW YORK (Reuters Health) - A new radiation treatment for breast cancer is becoming increasingly popular despite lack of good evidence, at least among well-insured Medicare patients, U.S. researchers say,.
NEW YORK (Reuters) - Amgen Inc's new osteoporosis drug denosumab delayed fractures and other bone problems in patients with advanced breast cancer five months longer than Novartis AG's Zometa, according to data from a large clinical trial.
LOS ANGELES (Reuters) - Combining experimental antibody drug pertuzumab with Herceptin, an antibody first approved in 1998, and chemotherapy shrank tumors in nearly half of newly diagnosed breast cancer patients treated in a clinical trial.
NEW YORK (Reuters) - The Novartis osteoporosis drug Zometa failed to improve disease free survival of early breast cancer patients in a large clinical trial, but some benefit was observed in older patients who took the medicine, researchers said.
CHICAGO (Reuters) - Half of U.S. women 40 and older do not get annual mammograms to screen for breast cancer, and nearly 40 percent of women 50 and older do not get the recommended biannual screenings, even though they have insurance.